Literature DB >> 7761444

A disaccharide that inhibits tumor necrosis factor alpha is formed from the extracellular matrix by the enzyme heparanase.

O Lider1, L Cahalon, D Gilat, R Hershkoviz, D Siegel, R Margalit, O Shoseyov, I R Cohen.   

Abstract

The activation of T cells by antigens or mitogens leads to the secretion of cytokines and enzymes that shape the inflammatory response. Among these molecular mediators of inflammation is a heparanase enzyme that degrades the heparan sulfate scaffold of the extracellular matrix (ECM). Activated T cells use heparanase to penetrate the ECM and gain access to the tissues. We now report that among the breakdown products of the ECM generated by heparanase is a trisulfated disaccharide that can inhibit delayed-type hypersensitivity (DTH) in mice. This inhibition of T-cell mediated inflammation in vivo was associated with an inhibitory effect of the disaccharide on the production of biologically active tumor necrosis factor alpha (TNF-alpha) by activated T cells in vitro; the trisulfated disaccharide did not affect T-cell viability or responsiveness generally. Both the in vivo and in vitro effects of the disaccharide manifested a bell-shaped dose-response curve. The inhibitory effects of the trisulfated disaccharide were lost if the sulfate groups were removed. Thus, the disaccharide, which may be a natural product of inflammation, can regulate the functional nature of the response by the T cell to activation. Such a feedback control mechanism could enable the T cell to assess the extent of tissue degradation and adjust its behavior accordingly.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7761444      PMCID: PMC41843          DOI: 10.1073/pnas.92.11.5037

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  15 in total

1.  A modified uronic acid carbazole reaction.

Authors:  T BITTER; H M MUIR
Journal:  Anal Biochem       Date:  1962-10       Impact factor: 3.365

2.  High-affinity binding of interferon-gamma to a basement membrane complex (matrigel).

Authors:  H Lortat-Jacob; H K Kleinman; J A Grimaud
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808

3.  Soluble antigen induces T lymphocytes to secrete an endoglycosidase that degrades the heparan sulfate moiety of subendothelial extracellular matrix.

Authors:  R Fridman; O Lider; Y Naparstek; Z Fuks; I Vlodavsky; I R Cohen
Journal:  J Cell Physiol       Date:  1987-01       Impact factor: 6.384

4.  Inhibition of T lymphocyte heparanase by heparin prevents T cell migration and T cell-mediated immunity.

Authors:  O Lider; Y A Mekori; T Miller; R Bar-Tana; I Vlodavsky; E Baharav; I R Cohen; Y Naparstek
Journal:  Eur J Immunol       Date:  1990-03       Impact factor: 5.532

5.  Heparanase activity expressed by platelets, neutrophils, and lymphoma cells releases active fibroblast growth factor from extracellular matrix.

Authors:  R Ishai-Michaeli; A Eldor; I Vlodavsky
Journal:  Cell Regul       Date:  1990-10

6.  Purification and properties of human platelet heparitinase.

Authors:  G M Oosta; L V Favreau; D L Beeler; R D Rosenberg
Journal:  J Biol Chem       Date:  1982-10-10       Impact factor: 5.157

Review 7.  Expression of heparanase by platelets and circulating cells of the immune system: possible involvement in diapedesis and extravasation.

Authors:  I Vlodavsky; A Eldor; A Haimovitz-Friedman; Y Matzner; R Ishai-Michaeli; O Lider; Y Naparstek; I R Cohen; Z Fuks
Journal:  Invasion Metastasis       Date:  1992

8.  Alternative cleavage of the cachectin/tumor necrosis factor propeptide results in a larger, inactive form of secreted protein.

Authors:  K Cseh; B Beutler
Journal:  J Biol Chem       Date:  1989-09-25       Impact factor: 5.157

9.  Suppression of experimental autoimmune diseases and prolongation of allograft survival by treatment of animals with low doses of heparins.

Authors:  O Lider; E Baharav; Y A Mekori; T Miller; Y Naparstek; I Vlodavsky; I R Cohen
Journal:  J Clin Invest       Date:  1989-03       Impact factor: 14.808

10.  Inhibition of heparanase-mediated degradation of extracellular matrix heparan sulfate by non-anticoagulant heparin species.

Authors:  M Bar-Ner; A Eldor; L Wasserman; Y Matzner; I R Cohen; Z Fuks; I Vlodavsky
Journal:  Blood       Date:  1987-08       Impact factor: 22.113

View more
  8 in total

1.  Disaccharides generated from heparan sulphate or heparin modulate chemokine-induced T-cell adhesion to extracellular matrix.

Authors:  R Hershkoviz; H Schor; A Ariel; I Hecht; I R Cohen; O Lider; L Cahalon
Journal:  Immunology       Date:  2000-01       Impact factor: 7.397

2.  Low-dose low-molecular weight heparin (enoxaparin) is effective as adjuvant treatment in active ulcerative colitis: an open trial.

Authors:  I Dotan; A Hallak; N Arber; M Santo; A Alexandrowitz; Y Knaani; R Hershkoviz; E Brazowski; Z Halpern
Journal:  Dig Dis Sci       Date:  2001-10       Impact factor: 3.199

3.  Circulating Heparan Sulfate Fragments Attenuate Histone-Induced Lung Injury Independently of Histone Binding.

Authors:  Yanlin Zhang; Sarah M Haeger; Yimu Yang; Kyrie L Dailey; Joshay A Ford; Eric P Schmidt
Journal:  Shock       Date:  2017-12       Impact factor: 3.454

4.  Heparanase 2 interacts with heparan sulfate with high affinity and inhibits heparanase activity.

Authors:  Flonia Levy-Adam; Sari Feld; Victoria Cohen-Kaplan; Anna Shteingauz; Miriam Gross; Gil Arvatz; Inna Naroditsky; Neta Ilan; Ilana Doweck; Israel Vlodavsky
Journal:  J Biol Chem       Date:  2010-06-24       Impact factor: 5.157

5.  Heparanase upregulates Th2 cytokines, ameliorating experimental autoimmune encephalitis.

Authors:  Menachem Bitan; Lola Weiss; Israel Reibstein; Michael Zeira; Yakov Fellig; Shimon Slavin; Eyal Zcharia; Arnon Nagler; Israel Vlodavsky
Journal:  Mol Immunol       Date:  2010-06       Impact factor: 4.407

6.  Role of endothelial heparanase in delayed-type hypersensitivity.

Authors:  Evgeny Edovitsky; Immanuel Lerner; Eyal Zcharia; Tamar Peretz; Israel Vlodavsky; Michael Elkin
Journal:  Blood       Date:  2005-12-29       Impact factor: 22.113

7.  Heparanase expression in periapical granulomas and radicular cysts.

Authors:  S Elad; Y Sherman; A Palmon; I Vlodavsky; R Or
Journal:  Odontology       Date:  2011-10-22       Impact factor: 2.634

8.  Heparanase mediates renal dysfunction during early sepsis in mice.

Authors:  Melissa I Lygizos; Yimu Yang; Christopher J Altmann; Kayo Okamura; Ana Andres Hernando; Mario J Perez; Lynelle P Smith; Daniel E Koyanagi; Aneta Gandjeva; Rhea Bhargava; Rubin M Tuder; Sarah Faubel; Eric P Schmidt
Journal:  Physiol Rep       Date:  2013-11-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.